Alphamab Oncology
http://www.alphamabonc.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alphamab Oncology
As China Prices Drop, Junshi Looks To Coherus To Take PD-1 Global
After Novartis, US firm Coherus leaps into the China immuno-oncology fray by licensing rights to innovative drugs from Shanghai's Junshi.
Affordable PD-1 From China? CStone Going Global With EQRx Onboard
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.
Pfizer Bets $480m On CStone And Surging China Immuno-Oncology Market
The latest big pharma vote of confidence in both the China market and R&D capabilities comes amid continuing standoffs with the US over a flurry of issues including the coronavirus, national security and trade, but as the pandemic seemingly recedes in China.
Coronavirus Update: Sinovac Latest To Report Vaccine Success In Humans
Sinovac's candidate is a more conventional inactivated vaccine, but is keeping pace with more modern approaches taken by Moderna and CanSino.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Alphamab Biopharmaceuticals Co., Ltd.
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
- Suzhou Alphamab Co., Ltd.